Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norwegian MRS (magnetic resonance spectroscopy) to improve cancer diagnosis

This article was originally published in Clinica

Executive Summary

A Norwegian research group claims to be the first to be the first to use in vivo magnetic resonance spectroscopy (MRS) to differentiate between benign and cancerous breast lesions in patients. The group, headed by Ingrid Gribbestad, senior research scientist at the Foundation for Scientific and Industrial Research at the Norwegian Institute of Technology in Trondheim, is using MRS to specifically document the presence of chemical substances in cancerous tumours.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel